These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27646783)

  • 1. Characterization and cholesterol management in patients with cardiovascular events and/or type 2 diabetes in the Netherlands.
    Heintjes E; Kuiper J; Lucius B; Penning-van Beest F; Kutikova L; Liem A; Herings R
    Curr Med Res Opin; 2017 Jan; 33(1):91-100. PubMed ID: 27646783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
    Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
    Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.
    Fadini GP; Frison V; Simioni N; Lapolla A; Gatti A; Bossi AC; Del Buono A; Fornengo P; Gottardo L; Laudato M; Perseghin G; Bonora E; Avogaro A
    J Am Heart Assoc; 2019 Jul; 8(14):e012244. PubMed ID: 31269877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
    Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
    JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.
    Ciriacks K; Coly G; Krishnaswami S; Patel SB; Kidambi S
    Metab Syndr Relat Disord; 2015 Mar; 13(2):84-90. PubMed ID: 25490061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins.
    Sakamoto K; Kawamura M; Kohro T; Omura M; Watanabe T; Ashidate K; Horiuchi T; Hara H; Sekine N; Chin R; Tsujino M; Hiyoshi T; Tagami M; Tanaka A; Mori Y; Inazawa T; Hirano T; Yamazaki T; Shiba T;
    PLoS One; 2015; 10(9):e0138332. PubMed ID: 26398887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
    Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P
    Cardiovasc Ther; 2012 Apr; 30(2):61-74. PubMed ID: 20626402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
    Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands.
    Kuiper JG; Sanchez RJ; Houben E; Heintjes EM; Penning-van Beest FJA; Khan I; van Riemsdijk M; Herings RMC
    Clin Ther; 2017 Apr; 39(4):819-827.e1. PubMed ID: 28347514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care database.
    Jameson K; Zhang Q; Zhao C; Ramey DR; Tershakovec AM; Gutkin SW; Marrett E
    Curr Med Res Opin; 2014 Apr; 30(4):655-65. PubMed ID: 24495126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.
    Karlson BW; Barter PJ; Palmer MK; Lundman P; Nicholls SJ
    Nutr Metab Cardiovasc Dis; 2012 Sep; 22(9):697-703. PubMed ID: 22705128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.